Standard BioTools announces recent paper published on NASH

Standard BioTools (LAB) announced a recent paper published in Nature Scientific Reports, by researchers at Pfizer (PFE) Research and Development, that detailed their use of the high-plex SomaScan Assay, leveraging an industry-leading 7,000-protein biomarker panel to analyze blood serum samples from patients in a Phase 2a clinical trial for nonalcoholic fatty liver disease, NAFLD, and NASH. “NASH and NAFLD are a significant challenge in terms of diagnosis and treatment, and the prevalence of metabolic and obesity-related diseases around the world has created a strong sense of urgency to learn more about them and find better ways of treating them,” said Standard BioTools Chief Medical Officer Stephen A. Williams, MD, PhD. “The SomaScan Assay gives us a view of the biological mechanisms of this disease with a simple blood draw from patients, and SomaSignal tests were shown in this study to be valuable in showing disease regression in patients.”